Part F | 29
728 Part F Marine Derived Metabolites
rine animal antineoplastic constituent Dolastatin 10, J. Am. Chem. Soc. 109, 6883–6885
(1987)
29.86
D.J. Newman, G.M. Cragg: Marine natural products and related compounds in clinical and advanced preclinical trials, J. Nat. Prod. 67, 1216–
1238 (2004)
29.87
M. Kobayashi, T. Natsume, S. Tamaoki, J. Watanabe, H. Asano, T. Mikami, K. Miyasaka,
K. Miyazaki, M. Gondo, K. Sakakibara, S. Tsukagoshi: Antitumor activity of TZT-1027, a novel
dolastatin 10 derivative, Jpn. J. Cancer Res. 88,
316–327 (1997)
29.88
P. Schöffski, B. Thate, G. Beutel, O. Bolte, O.D. Hofmann, M. Ganser, A. Jenner, P. Cheverton, J. Wanders, T. Oguma, R. Atsumi, M. Satomi: Phase I
and pharmaco kinetic study of TZT-1027, a novel
synthetic dolastatin 10 derivative, administered
as a 1-hour intravenous infusion every 3 weeks
in patients with advanced refractory cancer, Ann.
Oncol. 15, 671–679 (2004)
29.89
J. Liang, R.E. Moore, E.D. Moher, J.E. Munroe,
R.S. Al-awar, D.A. Hay, D.L. Varie, T.Y. Zhang,
J.A. Aikins, M.J. Martinelli, C. Shih, J.E. Ray,
L.L. Gibson, V. Vasudevan, L. Polin, K. White,
J. Kushner, C. Simpson, S. Pugh, T.H. Corbett:
Cryptophycins-309, 249 and other crypto phycin
analogs: Preclinical efficacy studies with mouse
and human tumors, Investig. New Drugs 23, 213–
224 (2005)
29.90
W. Fenical, P.R. Jensen, M.A. Palladino, K.S. Lam,
G.K. Lloyd, B.C. Potts: Discovery and development of the anticancer agent salinosporamide
A (NPI-0052), Bioorg. Med. Chem. 17, 2175–2180
(2009)
29.91
M. Groll, R. Huber, B.C.M. Potts: Crystal structures of salinosporamide A (NPI0052) and B
(NPI-0047) in complex with the 20S proteasome reveal important consequences of ˇlactone ring opening and a mechanism for irreversible binding, J. Am. Chem. Soc. 128, 5136–5141
(2006)
29.92
D. Chauhan, T. Hideshima, K.C. Anderson: A novel
proteasome
inhibitorNPI-0052asananticancer
therapy, Br. J. Cancer 95, 961–965 (2006)
29.93
K.S. Lam: From natural product to clinical trials:
NPI-0052 (salinosporamide A), a marine actinomycete derived anticancer agent. In: Natural
Products Chemistry for Drug Discovery, ed. by
A.D. Buss, M.S. Butler (Royal Society of Chemistry,
Cambridge 2010) pp. 355–373
29.94
P. Proksch, R.A. Edrada, E. Rainer: Drugs from the
sea opportunities and obstacles, Mar. Drugs 1, 5–
17 (2003)
29.95
J.B. Hart, R.E. Lill, S.J.H. Hickford, J.W. Blunt,
M.H.G. Munro: The halichondrins: Chemistry, biology, supply and delivery. In: Drugs from the Sea,
ed. by N. Fusetani (Karger, Basel 2000) pp. 134–
153
29.96
R. Montaser, H. Leusch: Marine natural products:
A new wave of drugs?, Future Med, Chem. 3(12),
1475–1489 (2011)
29.97
D. Mendola: Aquacultural production of bryostatin 1 and ecteinascidin 743. In: Drugs from the
Sea, ed. by N. Fusetani (Karger, Basel 2000) pp.
120–133
29.98
S. Sudek, N.B. Lopanik, L.E. Waggoner, M. Hildebrand, C. Anderson, H. Liu, A. Patel, D.H. Sherman, M.G. Haygood: Identification of the putative bryostatin polyketide synthase gene cluster
from Candidatus End obugula sertula, the uncultivated microbial symbiont of the marine bryozoan Bugula neritina, J. Nat. Prod. 70(1), 67–74
(2007)
29.99
C.V. Minh, P.V. Kiem, N.H. Dang: Marine natural
products and their potential application in the
future, AJSTD 22(4), 297–311 (2005)
29.100 J. Kennedy, B. Flemer, S.A. Jackson, D.P.H. Lejon,
J.P. Morrissey Fergal, O’Gara, A.D.W. Dobson: Marine Metagenomics: New tools for
the study and exploitation of marine microbial metabolism, Mar. Drugs 8, 608–628
(2010)
29.101 X.-Q. Zhao: Genome based studies of marine
microorganisms to maximize the diversity of natural products discovery for medical treatments,
Evidence-Based Complementary and Alternative
Medicine 2011, 384572 (2011)
29.102 Z.-Q. Xiong, J.-F. Wang, Y.-Y. Hao, Y. Wang: Recent advances in the discovery and development
of marine microbial natural products, Mar. Drugs
11, 700–717 (2013)
29.103 A.L. Lane, B.S. Moore: A sea of biosynthesis: Marine natural products meet the molecular age,
Nat. Prod. Rep. 28, 411–428 (2011)
29.104 S.S. Ebada, W.H. Lin, P. Proksch: Bioactive sesterterpenes and triterpenes from marine sponges:
Occurrence and pharmacological significance,
Mar. Drugs 8, 313–346 (2010)
29.105 M. Rhomer, M. Knani, P. Simonin, B. Sutter,
H. Sahm: Isoprenoid biosynthesis in bacteria:
A novel pathway for the early steps leading to
isopenthyl-diphosphate, Biochem. J. 295, 517–
524 (1993)
29.106 W. Capa-Robles, J. Paniagua-Michel, J.O. Soto:
The biosynthesis and accumulation of betacarotene in Dunaliella salina proceed via the
glyceraldehyde 3-hosphate/pyruvate pathway,
Nat. Prod. Res. 23(11), 1021–1028 (2009)
29.107 J. Paniagua-Michel, W. Capa-Robles, J. OlmosSoto, L.E. Gutierrez-Millan: The caroteno genesis
pathway via the isoprenoid-beta-carotene interference approach in a new strain of Dunaliella
salina isolated from Baja California Mexico, Mar.
Drugs 7(1), 45–56 (2009)
29.108 T.-S. Vo, S.-K. Kim: Fucoidan as a natural bioactive ingredient for functional foods, Funct. Foods
6(1), 16–27 (2013)
728 Part F Marine Derived Metabolites
rine animal antineoplastic constituent Dolastatin 10, J. Am. Chem. Soc. 109, 6883–6885
(1987)
29.86
D.J. Newman, G.M. Cragg: Marine natural products and related compounds in clinical and advanced preclinical trials, J. Nat. Prod. 67, 1216–
1238 (2004)
29.87
M. Kobayashi, T. Natsume, S. Tamaoki, J. Watanabe, H. Asano, T. Mikami, K. Miyasaka,
K. Miyazaki, M. Gondo, K. Sakakibara, S. Tsukagoshi: Antitumor activity of TZT-1027, a novel
dolastatin 10 derivative, Jpn. J. Cancer Res. 88,
316–327 (1997)
29.88
P. Schöffski, B. Thate, G. Beutel, O. Bolte, O.D. Hofmann, M. Ganser, A. Jenner, P. Cheverton, J. Wanders, T. Oguma, R. Atsumi, M. Satomi: Phase I
and pharmaco kinetic study of TZT-1027, a novel
synthetic dolastatin 10 derivative, administered
as a 1-hour intravenous infusion every 3 weeks
in patients with advanced refractory cancer, Ann.
Oncol. 15, 671–679 (2004)
29.89
J. Liang, R.E. Moore, E.D. Moher, J.E. Munroe,
R.S. Al-awar, D.A. Hay, D.L. Varie, T.Y. Zhang,
J.A. Aikins, M.J. Martinelli, C. Shih, J.E. Ray,
L.L. Gibson, V. Vasudevan, L. Polin, K. White,
J. Kushner, C. Simpson, S. Pugh, T.H. Corbett:
Cryptophycins-309, 249 and other crypto phycin
analogs: Preclinical efficacy studies with mouse
and human tumors, Investig. New Drugs 23, 213–
224 (2005)
29.90
W. Fenical, P.R. Jensen, M.A. Palladino, K.S. Lam,
G.K. Lloyd, B.C. Potts: Discovery and development of the anticancer agent salinosporamide
A (NPI-0052), Bioorg. Med. Chem. 17, 2175–2180
(2009)
29.91
M. Groll, R. Huber, B.C.M. Potts: Crystal structures of salinosporamide A (NPI0052) and B
(NPI-0047) in complex with the 20S proteasome reveal important consequences of ˇlactone ring opening and a mechanism for irreversible binding, J. Am. Chem. Soc. 128, 5136–5141
(2006)
29.92
D. Chauhan, T. Hideshima, K.C. Anderson: A novel
proteasome
inhibitorNPI-0052asananticancer
therapy, Br. J. Cancer 95, 961–965 (2006)
29.93
K.S. Lam: From natural product to clinical trials:
NPI-0052 (salinosporamide A), a marine actinomycete derived anticancer agent. In: Natural
Products Chemistry for Drug Discovery, ed. by
A.D. Buss, M.S. Butler (Royal Society of Chemistry,
Cambridge 2010) pp. 355–373
29.94
P. Proksch, R.A. Edrada, E. Rainer: Drugs from the
sea opportunities and obstacles, Mar. Drugs 1, 5–
17 (2003)
29.95
J.B. Hart, R.E. Lill, S.J.H. Hickford, J.W. Blunt,
M.H.G. Munro: The halichondrins: Chemistry, biology, supply and delivery. In: Drugs from the Sea,
ed. by N. Fusetani (Karger, Basel 2000) pp. 134–
153
29.96
R. Montaser, H. Leusch: Marine natural products:
A new wave of drugs?, Future Med, Chem. 3(12),
1475–1489 (2011)
29.97
D. Mendola: Aquacultural production of bryostatin 1 and ecteinascidin 743. In: Drugs from the
Sea, ed. by N. Fusetani (Karger, Basel 2000) pp.
120–133
29.98
S. Sudek, N.B. Lopanik, L.E. Waggoner, M. Hildebrand, C. Anderson, H. Liu, A. Patel, D.H. Sherman, M.G. Haygood: Identification of the putative bryostatin polyketide synthase gene cluster
from Candidatus End obugula sertula, the uncultivated microbial symbiont of the marine bryozoan Bugula neritina, J. Nat. Prod. 70(1), 67–74
(2007)
29.99
C.V. Minh, P.V. Kiem, N.H. Dang: Marine natural
products and their potential application in the
future, AJSTD 22(4), 297–311 (2005)
29.100 J. Kennedy, B. Flemer, S.A. Jackson, D.P.H. Lejon,
J.P. Morrissey Fergal, O’Gara, A.D.W. Dobson: Marine Metagenomics: New tools for
the study and exploitation of marine microbial metabolism, Mar. Drugs 8, 608–628
(2010)
29.101 X.-Q. Zhao: Genome based studies of marine
microorganisms to maximize the diversity of natural products discovery for medical treatments,
Evidence-Based Complementary and Alternative
Medicine 2011, 384572 (2011)
29.102 Z.-Q. Xiong, J.-F. Wang, Y.-Y. Hao, Y. Wang: Recent advances in the discovery and development
of marine microbial natural products, Mar. Drugs
11, 700–717 (2013)
29.103 A.L. Lane, B.S. Moore: A sea of biosynthesis: Marine natural products meet the molecular age,
Nat. Prod. Rep. 28, 411–428 (2011)
29.104 S.S. Ebada, W.H. Lin, P. Proksch: Bioactive sesterterpenes and triterpenes from marine sponges:
Occurrence and pharmacological significance,
Mar. Drugs 8, 313–346 (2010)
29.105 M. Rhomer, M. Knani, P. Simonin, B. Sutter,
H. Sahm: Isoprenoid biosynthesis in bacteria:
A novel pathway for the early steps leading to
isopenthyl-diphosphate, Biochem. J. 295, 517–
524 (1993)
29.106 W. Capa-Robles, J. Paniagua-Michel, J.O. Soto:
The biosynthesis and accumulation of betacarotene in Dunaliella salina proceed via the
glyceraldehyde 3-hosphate/pyruvate pathway,
Nat. Prod. Res. 23(11), 1021–1028 (2009)
29.107 J. Paniagua-Michel, W. Capa-Robles, J. OlmosSoto, L.E. Gutierrez-Millan: The caroteno genesis
pathway via the isoprenoid-beta-carotene interference approach in a new strain of Dunaliella
salina isolated from Baja California Mexico, Mar.
Drugs 7(1), 45–56 (2009)
29.108 T.-S. Vo, S.-K. Kim: Fucoidan as a natural bioactive ingredient for functional foods, Funct. Foods
6(1), 16–27 (2013)